

Ben Forbes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1529883/publications.pdf>

Version: 2024-02-01

87
papers

3,022
citations

172207

29
h-index

174990

52
g-index

90
all docs

90
docs citations

90
times ranked

3571
citing authors

#	ARTICLE	IF	CITATIONS
1	Culture of Calu-3 Cells at the Air Interface Provides a Representative Model of the Airway Epithelial Barrier. <i>Pharmaceutical Research</i> , 2006, 23, 1482-1490.	1.7	305
2	Human respiratory epithelial cell culture for drug delivery applications. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2005, 60, 193-205.	2.0	266
3	Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. <i>European Journal of Pharmaceutical Sciences</i> , 2007, 31, 73-84.	1.9	200
4	Human airway epithelial cell lines for in vitro drug transport and metabolism studies. <i>Pharmaceutical Science & Technology Today</i> , 2000, 3, 18-27.	0.7	126
5	The human bronchial epithelial cell line 16HBE14oâ€™ as a model system of the airways for studying drug transport. <i>International Journal of Pharmaceutics</i> , 2003, 257, 161-167.	2.6	112
6	Challenges in inhaled product development and opportunities for open innovation. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 69-87.	6.6	95
7	Quantitative assessment of nanoparticle surface hydrophobicity and its influence on pulmonary biocompatibility. <i>Journal of Controlled Release</i> , 2014, 183, 94-104.	4.8	73
8	Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses. <i>Advanced Drug Delivery Reviews</i> , 2014, 71, 15-33.	6.6	72
9	The delivered dose: Applying particokinetics to in vitro investigations of nanoparticle internalization by macrophages. <i>Journal of Controlled Release</i> , 2012, 162, 259-266.	4.8	66
10	Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters. <i>Pharmaceutics</i> , 2020, 12, 599.	2.0	61
11	Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 113, 41-52.	1.9	57
12	Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1033-1043.	1.7	54
13	Drug permeability in 16HBE14o- airway cell layers correlates with absorption from the isolated perfused rat lung. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 26, 414-420.	1.9	52
14	Rapid characterisation of the inherent dispersibility of respirable powders using dry dispersion laser diffraction. <i>International Journal of Pharmaceutics</i> , 2013, 447, 124-131.	2.6	49
15	A Biocompatible Synthetic Lung Fluid Based on Human Respiratory Tract Lining Fluid Composition. <i>Pharmaceutical Research</i> , 2017, 34, 2454-2465.	1.7	49
16	In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches. <i>AAPS Journal</i> , 2015, 17, 837-852.	2.2	48
17	In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 83-89.	2.0	46
18	Improving Drug Delivery for Alzheimerâ€™s Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 4373-4390.	3.3	46

#	ARTICLE	IF	CITATIONS
19	Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers. <i>International Journal of Pharmaceutics</i> , 2014, 465, 42-51.	2.6	45
20	Brake dust exposure exacerbates inflammation and transiently compromises phagocytosis in macrophages. <i>Metalomics</i> , 2020, 12, 371-386.	1.0	45
21	Formulation Pre-screening of Inhalation Powders Using Computational Atom-Atom Systematic Search Method. <i>Molecular Pharmaceutics</i> , 2015, 12, 18-33.	2.3	43
22	Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery. <i>International Journal of Pharmaceutics</i> , 2017, 517, 286-295.	2.6	41
23	In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 293-301.	1.2	38
24	Naloxone without the needle – systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. <i>Drug and Alcohol Dependence</i> , 2016, 163, 16-23.	1.6	38
25	Surface Chemistry of Photoluminescent F8BT Conjugated Polymer Nanoparticles Determines Protein Corona Formation and Internalization by Phagocytic Cells. <i>Biomacromolecules</i> , 2015, 16, 733-742.	2.6	36
26	Characterisation of nasal devices for delivery of insulin to the brain and evaluation in humans using functional magnetic resonance imaging. <i>Journal of Controlled Release</i> , 2019, 302, 140-147.	4.8	34
27	Paraben Transport and Metabolism in the Biomimetic Artificial Membrane Permeability Assay (BAMPA) and 3-Day and 21-Day Caco-2 Cell Systems. <i>Journal of Biomolecular Screening</i> , 2007, 12, 84-91.	2.6	32
28	Design and development of a biorelevant simulated human lung fluid. <i>Journal of Drug Delivery Science and Technology</i> , 2018, 47, 485-491.	1.4	32
29	The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers. <i>International Journal of Pharmaceutics</i> , 2011, 409, 164-168.	2.6	31
30	Inflammatory Response and Barrier Properties of a New Alveolar Type 1-Like Cell Line (TT1). <i>Pharmaceutical Research</i> , 2009, 26, 1172-1180.	1.7	29
31	Drug metabolism in the lungs: opportunities for optimising inhaled medicines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 611-625.	1.5	27
32	A Comparison of Drug Transport in Pulmonary Absorption Models: Isolated Perfused rat Lungs, Respiratory Epithelial Cell Lines and Primary Cell Culture. <i>Pharmaceutical Research</i> , 2017, 34, 2532-2540.	1.7	25
33	Glycerol Solvates DPPC Headgroups and Localizes in the Interfacial Regions of Model Pulmonary Interfaces Altering Bilayer Structure. <i>Langmuir</i> , 2018, 34, 6941-6954.	1.6	25
34	Dissolution of Intact, Divided and Crushed Circadin Tablets: Prolonged vs. Immediate Release of Melatonin. <i>Pharmaceutics</i> , 2016, 8, 2.	2.0	24
35	Imaging drugs, metabolites and biomarkers in rodent lung: a DESI MS strategy for the evaluation of drug-induced lipidosis. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 8023-8032.	1.9	24
36	Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies. <i>International Journal of Pharmaceutics</i> , 2022, 620, 121720.	2.6	23

#	ARTICLE	IF	CITATIONS
37	Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2234-2244.	1.6	22
38	Formulating powderâ€“device combinations for salmeterol xinafoate dry powder inhalers. <i>International Journal of Pharmaceutics</i> , 2015, 490, 360-367.	2.6	21
39	In vitro and in vivo antitubercular activity of benzothiazinone-loaded human serum albumin nanocarriers designed for inhalation. <i>Journal of Controlled Release</i> , 2020, 328, 339-349.	4.8	21
40	The Synthesis of High Molecular Weight Partially Hydrolysed Poly(vinyl alcohol) Grades Suitable for Nanoparticle Fabrication. <i>Journal of Nanoscience and Nanotechnology</i> , 2008, 8, 5739-5747.	0.9	20
41	Triggered-release nanocapsules for drug delivery to the lungs. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 89-97.	1.7	20
42	Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 313-321.	1.6	20
43	Optimisation of the Caco-2 Permeability Assay Using Experimental Design Methodology. <i>Pharmaceutical Research</i> , 2008, 25, 1544-1551.	1.7	18
44	Use of PBPK Modeling To Evaluate the Performance of Dissolv<i>It</i>, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products. <i>Molecular Pharmaceutics</i> , 2019, 16, 1245-1254.	2.3	18
45	Engineering of konjac glucomannan into respirable microparticles for delivery of antitubercular drugs. <i>International Journal of Pharmaceutics</i> , 2021, 604, 120731.	2.6	18
46	Development of new in vitro models of lung protease activity for investigating stability of inhaled biological therapies and drug delivery systems. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 146, 64-72.	2.0	17
47	A consensus research agenda for optimising nasal drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 127-132.	2.4	16
48	Exploiting Endocytosis for Non-Spherical Nanoparticle Cellular Uptake. <i>Nanomanufacturing</i> , 2022, 2, 1-16.	1.8	16
49	Lost in translation: what is stopping inhaled nanomedicines from realizing their potential?. <i>Therapeutic Delivery</i> , 2014, 5, 757-761.	1.2	15
50	In Vitro Multiparameter Assay Development Strategy toward Differentiating Macrophage Responses to Inhaled Medicines. <i>Molecular Pharmaceutics</i> , 2015, 12, 2675-2687.	2.3	15
51	Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration. <i>Journal of Controlled Release</i> , 2016, 235, 24-33.	4.8	15
52	Morphometric Characterization of Rat and Human Alveolar Macrophage Cell Models and their Response to Amiodarone using High Content Image Analysis. <i>Pharmaceutical Research</i> , 2017, 34, 2466-2476.	1.7	14
53	Intranasal insulin administration decreases cerebral blood flow in corticoâ€“limbic regions: A neuropharmacological imaging study in normal and overweight males. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 175-185.	2.2	14
54	Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in <i>mdr1a</i>-deficient and <i>mdr1a</i>-competent mice. <i>Journal of Pharmacy and Pharmacology</i> , 2008, 60, 1305-1310.	1.2	14

#	ARTICLE	IF	CITATIONS
55	In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 293-301.	1.2	14
56	The airways microbiome of individuals with asthma treated with high and low doses of inhaled corticosteroids. <i>PLoS ONE</i> , 2020, 15, e0244681.	1.1	14
57	Drug Delivery Devices for Inhaled Medicines. <i>Handbook of Experimental Pharmacology</i> , 2016, 237, 265-280.	0.9	13
58	Amorphous Formulation and <i>In Vitro</i> Performance Testing of Instantly Disintegrating Buccal Tablets for the Emergency Delivery of Naloxone. <i>Molecular Pharmaceutics</i> , 2016, 13, 1688-1698.	2.3	13
59	<i>In Silico</i> and <i>In Vitro</i> Screening for P-Glycoprotein Interaction with Tenofovir, Darunavir, and Dapivirine: An Antiretroviral Drug Combination for Topical Prevention of Colorectal HIV Transmission. <i>Molecular Pharmaceutics</i> , 2017, 14, 2660-2669.	2.3	13
60	iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System. <i>Molecular Pharmaceutics</i> , 2022, 19, 2032-2039.	2.3	13
61	Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 2517-2521.	1.7	12
62	iBCS: 2. Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes. <i>Molecular Pharmaceutics</i> , 2022, 19, 2040-2047.	2.3	12
63	Formulation of Inhaled Medicines: Effect of Delivery Vehicle on Immortalized Epithelial Cells. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2000, 13, 281-288.	1.2	11
64	A poly(vinyl alcohol) nanoparticle platform for kinetic studies of inhaled particles. <i>Inhalation Toxicology</i> , 2009, 21, 631-640.	0.8	11
65	Ion-Pairing with Spermine Targets Theophylline To the Lungs via the Polyamine Transport System. <i>Molecular Pharmaceutics</i> , 2018, 15, 861-870.	2.3	11
66	Comparison of Oral, Intranasal and Aerosol Administration of Amiodarone in Rats as a Model of Pulmonary Phospholipidosis. <i>Pharmaceutics</i> , 2019, 11, 345.	2.0	11
67	Evidence for the existence of powder sub-populations in micronized materials: Aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.. <i>Pharmaceutical Research</i> , 2014, 31, 3251-3264.	1.7	9
68	The Isolated Perfused Lung for Drug Absorption Studies. , 2008, , 135-163.		9
69	What are the biological and therapeutic implications of biomolecule corona formation on the surface of inhaled nanomedicines?. <i>Nanomedicine</i> , 2015, 10, 343-345.	1.7	8
70	Mucus penetrating properties of soft, distensible lipid nanocapsules. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 139, 76-84.	2.0	8
71	Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 3861-3869.	1.6	7
72	Solid-state epimerisation and disproportionation of pilocarpine HCl: Why we need a 5-stage approach to validate melting point measurements for heat-sensitive drugs. <i>International Journal of Pharmaceutics</i> , 2020, 574, 118869.	2.6	7

#	ARTICLE	IF	CITATIONS
73	Recommendations for crushing Circadin® (melatonin) tablets for safe and reliable delivery via pediatric nasogastric tubes. <i>International Journal of Pharmaceutics</i> , 2021, 594, 120151.	2.6	6
74	RespiCell™: An Innovative Dissolution Apparatus for Inhaled Products. <i>Pharmaceutics</i> , 2021, 13, 1541.	2.0	6
75	Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in <i>mdr1a</i> -deficient and <i>mdr1a</i> -competent mice. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 1305-1310.	1.2	5
76	Modelling the effects of microgravity on the permeability of air interface respiratory epithelial cell layers. <i>Advances in Space Research</i> , 2010, 46, 712-718.	1.2	4
77	Controlled drug release from lung-targeted nanocarriers via chemically mediated shell permeabilisation. <i>International Journal of Pharmaceutics</i> , 2016, 511, 1033-1041.	2.6	4
78	Using Polar Ion-Pairs to Control Drug Delivery to the Airways of the Lungs. <i>Molecular Pharmaceutics</i> , 2020, 17, 1482-1490.	2.3	4
79	In vitro Fourier transform infrared spectroscopic study of the effect of glycerol on the uptake of beclomethasone dipropionate in living respiratory cells. <i>International Journal of Pharmaceutics</i> , 2021, 609, 121118.	2.6	4
80	Pulmonary Epithelial Cell Culture. , 2002, 188, 65-75.		3
81	Realising the potential of various inhaled airway challenge agents through improved delivery to the lungs. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 27-35.	1.1	3
82	Epithelial permeability and drug absorption in the lungs. , 2021, , 267-299.		3
83	Fluticasone Particles Bind to Motile Respiratory Cilia: A Mechanism for Enhanced Lung and Systemic Exposure?. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020, 34, 181-188.	0.7	2
84	A Cyclodextrin-Stabilized Spermine-Tagged Drug Triplex that Targets Theophylline to the Lungs Selectively in Respiratory Emergency. <i>Advanced Therapeutics</i> , 2020, 3, 2000153.	1.6	2
85	An in vitro bioassay for evaluating the effect of inhaled bronchodilators on airway smooth muscle. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 63, 101943.	1.1	0
86	Thermosensitive Nasal In Situ Gels of Lipid-Based Nanosystems to Improve the Treatment of Alzheimer's Disease. <i>Proceedings (mdpi)</i> , 2020, 78, .	0.2	0
87	Characterizing RAPID™ platelet and leukocyte-rich plasma gels as an autologous, point-of-care medicine for diabetic foot ulcer treatment.. <i>British Journal of Pharmacy</i> , 0, , .	0.1	0